GSEP
AXSM icon

Golden State Equity Partners’s Axsome Therapeutics AXSM Stock Holding History

Golden State Equity Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3K Buy
+67
New +$11.6K ﹤0.01% 1262

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Golden State Equity Partners's AXSM Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 67 shares worth $11.3K. The stake represents ﹤0.01% of the portfolio and ranks #1262 among its holdings.

409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Golden State Equity Partners held 67 shares of Axsome Therapeutics worth $11.3K as of Q1 2026.
  • Axsome Therapeutics was a new Golden State Equity Partners position in Q1 2026.
  • Axsome Therapeutics made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #1262 holding.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.